The DOI matches its Crossref record; 154 of the 154 references it cites were found in a registry or an index.
The MPTP model of Parkinson's disease
Abstract
The biochemical and cellular changes that occur following administration of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) are remarkably similar to that seen in idiopathic Parkinson's disease (PD). In this review, we detail the molecular activities of this compound from peripheral intoxication through its various biotransformations. In addition, we detail the interplay that occurs between the different cellular compartments (neurons and glia) that eventually consort to kill substantia nigra pars compacta (SNpc) neurons.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Chronic systemic pesticide exposure reproduces features of Parkinson's disease
Betarbet, R., Sherer, T. B., MacKenzie, G., Garcia-Osuna, M., Panov, A. V., & Greenamyre, J. T. (2000) · Nature Neuroscience · doi:10.1038/81834 · Cited by 3,683
Genetic Dissection of Complex Traits
Lander, E. S., & Schork, N. J. (1994) · Science · doi:10.1126/science.8091226 · Cited by 3,413
THE HEME OXYGENASE SYSTEM:A Regulator of Second Messenger Gases
Maines, M. D. (1997) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.37.1.517 · Cited by 2,505
The substantia nigra of the human brain
Damier, P., Hirsch, E. C., Agid, Y., & Graybiel, A. M. (1999) · Brain · doi:10.1093/brain/122.8.1437 · Cited by 1,756
Giasson, B. I., Duda, J. E., Murray, I. V. J., Chen, Q., Souza, J. M., Hurtig, H. I., Ischiropoulos, H., Trojanowski, J. Q., & -Y. Lee, V. M. (2000) · Science · doi:10.1126/science.290.5493.985 · Cited by 1,546
Conway, K. A., Harper, J. D., & Lansbury, P. T. (1998) · Nature Medicine · doi:10.1038/3311 · Cited by 1,499
Nicklas, W. J., Vyas, I., & Heikkila, R. E. (1985) · Life Sciences · doi:10.1016/0024-3205(85)90146-8 · Cited by 1,262
Wu, D. C., Jackson-Lewis, V., Vila, M., Tieu, K., Teismann, P., Vadseth, C., Choi, D.-K., Ischiropoulos, H., & Przedborski, S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-05-01763.2002 · Cited by 1,183
Oxidative Pathways for Catecholamines in the Genesis of Neuromelanin and Cytotoxic Quinones
GRAHAM, D. G. (1978) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13535-9 · Cited by 1,126
Liberatore, G. T., Jackson-Lewis, V., Vukosavic, S., Mandir, A. S., Vila, M., McAuliffe, W. G., Dawson, V. L., Dawson, T. M., & Przedborski, S. (1999) · Nature Medicine · doi:10.1038/70978 · Cited by 1,046
Self-citationHeme oxygenase 1 is required for mammalian iron reutilization
Poss, K. D., & Tonegawa, S. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.20.10919 · Cited by 1,016
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study
Whone, A. L., Watts, R. L., Stoessl, A. J., Davis, M., Reske, S., Nahmias, C., Lang, A. E., Rascol, O., Ribeiro, M. J., Remy, P., et al. (2003) · Annals of Neurology · doi:10.1002/ana.10609 · Cited by 829
Parkinson’s Disease and Movement Disorders
(2005) · Jaypee Brothers Medical Publishers (P) Ltd. eBooks · doi:10.5005/jp/books/10587 · Cited by 798
Modeling Parkinson's Disease in Rats: An Evaluation of 6-OHDA Lesions of the Nigrostriatal Pathway
Deumens, R., Blokland, A., & Prickaerts, J. (2002) · Experimental Neurology · doi:10.1006/exnr.2002.7891 · Cited by 758
SCHWARTING, R., & HUSTON, J. (1996) · Progress in Neurobiology · doi:10.1016/s0301-0082(96)00040-8 · Cited by 737
Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration
Teismann, P., Tieu, K., Choi, D.-K., Wu, D.-C., Naini, A., Hunot, S., Vila, M., Jackson-Lewis, V., & Przedborski, S. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0837397100 · Cited by 660
Self-citationPeroxynitrite reactions and formation in mitochondria
Radi, R., Cassina, A., Hodara, R., Quijano, C., & Castro, L. (2002) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(02)01111-5 · Cited by 635
Wu, D.-C., Teismann, P., Tieu, K., Vila, M., Jackson-Lewis, V., Ischiropoulos, H., & Przedborski, S. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0937239100 · Cited by 633
Self-citationPrzedborski, S., Jackson-Lewis, V, Yokoyama, R., Shibata, T., Dawson, V. L., & Dawson, T. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.10.4565 · Cited by 624
Self-citationParkinson's Disease and Movement Disorders
Kieburtz, K. (1994) · Archives of Neurology · doi:10.1001/archneur.1994.00540220013003 · Cited by 616
Peroxynitrite‐mediated oxidative protein modifications
Ischiropoulos, H., & Al-Mehdi, A. B. (1995) · FEBS Letters · doi:10.1016/0014-5793(95)00307-u · Cited by 609
Jackson-Lewis, V., Jakowec, M., Burke, R. E., & Przedborski, S. (1995) · Neurodegeneration · doi:10.1016/1055-8330(95)90015-2 · Cited by 609
Self-citationA cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter
Liu, Y. (1992) · Cell · doi:10.1016/0092-8674(92)90425-c · Cited by 594
Dringen, R., Pfeiffer, B., & Hamprecht, B. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-02-00562.1999 · Cited by 589
Dityrosine Cross-linking Promotes Formation of Stable α-Synuclein Polymers
Souza, J. M., Giasson, B. I., Chen, Q., Lee, V. M.-Y., & Ischiropoulos, H. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000206200 · Cited by 563
Mitochondria, Oxidative Damage, and Inflammation in Parkinson's Disease
BEAL, M. F. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07470.x · Cited by 523
Changes in cytokines and neurotrophins in Parkinson’s disease
Nagatsu, T., Mogi, M., Ichinose, H., & Togari, A. (2000) · Advances in Research on Neurodegeneration · doi:10.1007/978-3-7091-6301-6_19 · Cited by 510
Inflammatory Regulators in Parkinson's Disease: iNOS, Lipocortin-1, and Cyclooxygenases-1 and -2
Knott, C., Stern, G., & Wilkin, G. P. (2000) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.2000.0914 · Cited by 503
Prevalence of Parkinson's disease in the elderly: The Rotterdam Study
de Rijk, M. C., Breteler, M. M. B., Graveland, G. A., Ott, A., Grobbee, D. E., van der Meche, F. G. A., & Hofman, A. (1995) · Neurology · doi:10.1212/wnl.45.12.2143 · Cited by 488
Thiruchelvam, M., Richfield, E. K., Baggs, R. B., Tank, A. W., & Cory-Slechta, D. A. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-24-09207.2000 · Cited by 471
Spina, M. B., Squinto, S. P., Miller, J., Lindsay, R. M., & Hyman, C. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb08880.x · Cited by 460
Przedborski, S., Kostic, V, Jackson-Lewis, V, Naini, A., Simonetti, S., Fahn, S., Carlson, E., Epstein, C., & Cadet, J. (1992) · The Journal of Neuroscience · doi:10.1523/jneurosci.12-05-01658.1992 · Cited by 456
Self-citationTakahashi, N., Miner, L. L., Sora, I., Ujike, H., Revay, R. S., Kostic, V., Jackson-Lewis, V., Przedborski, S., & Uhl, G. R. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.18.9938 · Cited by 429
Self-citationParaquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss
Brooks, A. I., Chadwick, C. A., Gelbard, H. A., Cory-Slechta, D. A., & Federoff, H. J. (1999) · Brain Research · doi:10.1016/s0006-8993(98)01192-5 · Cited by 424
Ara, J., Przedborski, S., Naini, A. B., Jackson-Lewis, V., Trifiletti, R. R., Horwitz, J., & Ischiropoulos, H. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7659 · Cited by 414
Self-citationRamsay, R. R., & Singer, T. P. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)57434-8 · Cited by 412
Hunot, S., Dugas, N., Faucheux, B., Hartmann, A., Tardieu, M., Debré, P., Agid, Y., Dugas, B., & Hirsch, E. C. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-09-03440.1999 · Cited by 408
Midbrain dopaminergic cell loss in parkinson's disease: Computer visualization
German, D. C., Manaye, K., Smith, W. K., Woodward, D. J., & Saper, C. B. (1989) · Annals of Neurology · doi:10.1002/ana.410260403 · Cited by 396
Dopamine transporters and neuronal injury
Miller, G. W., Gainetdinov, R. R., Levey, A. I., & Caron, M. G. (1999) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(99)01379-6 · Cited by 371
Cleeter, M. W. J., Cooper, J. M., & Schapira, A. H. V. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb09789.x · Cited by 371
Monte, D. A. D. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00501-5 · Cited by 361
Enzymatic Oxidation of Dopamine: The Role of Prostaglandin H Synthase
Hastings, T. G. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.64020919.x · Cited by 359
Gainetdinov, R. R., Fumagalli, F., Jones, S. R., & Caron, M. G. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69031322.x · Cited by 353
Glial cells and inflammation in parkinson's disease: A role in neurodegeneration?
Hirsch, E. C., Hunot, S., Damier, P., & Faucheux, B. (1998) · Annals of Neurology · doi:10.1002/ana.410440717 · Cited by 334
Schäbitz, W.-R., Sommer, C., Zoder, W., Kiessling, M., Schwaninger, M., & Schwab, S. (2000) · Stroke · doi:10.1161/01.str.31.9.2212 · Cited by 325
Heme Oxygenase: Recent Advances in Understanding Its Regulation and Role
Elbirt, K. K., & Bonkovsky, H. L. (1999) · Proceedings of the Association of American Physicians · doi:10.1111/paa.1999.111.5.438 · Cited by 308
Neural Heme Oxygenase-1 Expression in Idiopathic Parkinson's Disease
Schipper, H. M., Liberman, A., & Stopa, E. G. (1998) · Experimental Neurology · doi:10.1006/exnr.1997.6752 · Cited by 300
Selectivity of the Parkinsonian Neurotoxin MPTP: Toxic Metabolite MPP + Binds to Neuromelanin
D'Amato, R. J., Lipman, Z. P., & Snyder, S. H. (1986) · Science · doi:10.1126/science.3080808 · Cited by 296
MPTP Toxicity: Implications for Research in Parkinson's Disease
Kopin, I. J., & Markey, S. P. (1988) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.11.030188.000501 · Cited by 295
The cells of origin of nigrotectal, nigrothalamic and nigrostriatal projections in the rat
Faull, R. L. M., & Mehler, W. R. (1978) · Neuroscience · doi:10.1016/0306-4522(78)90119-7 · Cited by 293
Przedborski, S., & Vila, M. (2003) · PubMed · Cited by 286
PRZEDBORSKI, S., & VILA, M. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07476.x · Cited by 283
Astrocytes Provide Cysteine to Neurons by Releasing Glutathione
Wang, X. F., & Cynader, M. S. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0741434.x · Cited by 281
Pathogenic role of glial cells in Parkinson's disease
Teismann, P., Tieu, K., Cohen, O., Choi, D., Wu, D. C., Marks, D., Vila, M., Jackson‐Lewis, V., & Przedborski, S. (2003) · Movement Disorders · doi:10.1002/mds.10332 · Cited by 275
Self-citationRegional and Cell-Specific Expression of GDNF in Rat Brain
Scharr, D. G., Sieber, B.-A., Dreyfus, C. F., & Black, I. B. (1993) · Experimental Neurology · doi:10.1006/exnr.1993.1207 · Cited by 272
Frim, D. M., Uhler, T. A., Galpern, W. R., Beal, M. F., Breakefield, X. O., & Isacson, O. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.11.5104 · Cited by 269
Hydroxyl radical attack on dopamine.
Slivka, A., & Cohen, G. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)36277-4 · Cited by 264
IV. MPTP, MPP+ and mitochondrial function
Nicklas, W. J., Youngster, S. K., Kindt, M. V., & Heikkila, R. E. (1987) · Life Sciences · doi:10.1016/0024-3205(87)90299-2 · Cited by 257
. Chun, H. S., Gibson, G. E., DeGiorgio, L. A., Zhang, H., Kidd, V. J., & Son, J. H. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00096.x · Cited by 256
Pathophysiology of Parkinson's Disease: The MPTP Primate Model of the Human Disorder
WICHMANN, T., & DeLONG, M. R. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07477.x · Cited by 255
The parkinsonian toxin MPTP: action and mechanism
Przedborski, S., Jackson-Lewis, V., Djaldetti, R., Liberatore, G., Vila, M., Vukosavic, S., & Almer, G. (2000) · Restorative Neurology and Neuroscience · doi:10.3233/rnn-2000-00132 · Cited by 252
Self-citationBurns, R. S., LeWitt, P. A., Ebert, M. H., Pakkenberg, H., & Kopin, I. J. (1985) · New England Journal of Medicine · doi:10.1056/nejm198505303122203 · Cited by 244
Louis, E. D., Mayer, S. A., & Rowland, L. P. (2001) · Cited by 243
Absence of MPTP-Induced Neuronal Death in Mice Lacking the Dopamine Transporter
Bezard, E., Gross, C. E., Fournier, M.-C., Dovero, S., Bloch, B., & Jaber, M. (1999) · Experimental Neurology · doi:10.1006/exnr.1998.6995 · Cited by 230
Chapter 36: Astrocytes and Parkinson's disease
Forno, L. S., DeLanney, L. E., Irwin, I., Monte, D. D., & Langston, J. W. (1992) · Progress in Brain Research · doi:10.1016/s0079-6123(08)61770-7 · Cited by 230
Rate of progression in Parkinson's disease: A 6‐[18F]fluoro‐L‐dopa PET study
Nurmi, E., Ruottinen, H. M., Bergman, J., Haaparanta, M., Solin, O., Sonninen, P., & Rinne, J. O. (2001) · Movement Disorders · doi:10.1002/mds.1139 · Cited by 219
Giasson, B. I., Jakes, R., Goedert, M., Duda, J. E., Leight, S., Trojanowski, J. Q., & Lee, V. M. Y. (2000) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(20000215)59:4<528::aid-jnr8>3.0.co;2-0 · Cited by 218
The Role of Iron in Neurodegeneration: Prospects for Pharmacotherapy of Parkinson??s Disease
Jellinger, K. A. (1999) · Drugs & Aging · doi:10.2165/00002512-199914020-00004 · Cited by 218
Immunochemical Analysis of Vesicular Monoamine Transporter (VMAT2) Protein in Parkinson's Disease
Miller, G. W., Erickson, J. D., Perez, J. T., Penland, S. N., Mash, D. C., Rye, D. B., & Levey, A. I. (1999) · Experimental Neurology · doi:10.1006/exnr.1998.7008 · Cited by 215
Astrocytes convert the parkinsonism inducing neurotoxin, MPTP, to its active metabolite, MPP+
Ransom, B. R., Kunis, D. M., Irwin, I., & Langston, J. W. (1987) · Neuroscience Letters · doi:10.1016/0304-3940(87)90543-x · Cited by 209
Sunstro¨m, E., Stro¨mberg, I., Tsutsumi, T., Olson, L., & Jonsson, G. (1987) · Brain Research · doi:10.1016/0006-8993(87)90986-3 · Cited by 204
Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson's disease
Müller, T., Büttner, T., Gholipour, A.-F., & Kuhn, W. (2003) · Neuroscience Letters · doi:10.1016/s0304-3940(03)00185-x · Cited by 203
Przedborski, S., Chen, Q., Vila, M., Giasson, B. I., Djaldatti, R., Vukosavic, S., Souza, J. M., Jackson‐Lewis, V., Lee, V. M. ‐., & Ischiropoulos, H. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00174.x · Cited by 190
Self-citationRamsay, R. R., Dadgar, J., Trevor, A., & Singer, T. P. (1986) · Life Sciences · doi:10.1016/0024-3205(86)90037-8 · Cited by 181
Increased MPTP Neurotoxicity in Vesicular Monoamine Transporter 2 Heterozygote Knockout Mice
Gainetdinov, R. R., Fumagalli, F., Wang, Y., Jones, S. R., Levey, A. I., Miller, G. W., & Caron, M. G. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.70051973.x · Cited by 178
Skaper, S. D., Floreani, M., Negro, A., Facci, L., & Giusti, P. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.70051859.x · Cited by 176
Glial cell reactions in neurodegenerative diseases: pathophysiology and therapeutic interventions.
McGeer, P. L., & McGeer, E. G. (1998) · PubMed · Cited by 158
The heme oxygenase system and its functions in the brain.
Maines, M. D. (2000) · PubMed · Cited by 157
LaVoie, M. J., & Hastings, T. G. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0732546.x · Cited by 150
Role of α-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice
Schlüter, O. M., Fornai, F., Alessandri, M., TAKAMORI, S., Geppert, M., Jahn, R., & Südhof, T. C. (2003) · Neuroscience · doi:10.1016/s0306-4522(03)00036-8 · Cited by 147
Comparative studies on the mechanisms of paraquat and 1-methyl-4-phenylpyridine (MPP+) cytotoxicity
Monte, D. A. D., Sandy, M. S., Ekström, G., & Smith, M. T. (1986) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(86)91210-6 · Cited by 145
Muthane, U. B., Ramsay, K., Jiang, H., Jackson-Lewis, V. R., Donaldson, D. M., Fernando, S., Ferreira, M., & Przedborski, S. (1994) · Experimental Neurology · doi:10.1006/exnr.1994.1058 · Cited by 143
Self-citationTsukahara, T., Takeda, M., Shimohama, S., Ohara, O., & Hashimoto, N. (1995) · Neurosurgery · doi:10.1227/00006123-199510000-00018 · Cited by 134
Hamre, K., Tharp, R., Poon, K. K.-Y., Xiong, X., & Smeyne, R. J. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01273-1 · Cited by 132
Self-citationMcNaught, K. S. P., & Jenner, P. G. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0732469.x · Cited by 132
Excitotoxicity of l-DOPA and 6-OH-DOPA: Implications for Parkinson's and Huntington's diseases
Olney, J. W., Zorumski, C. F., Stewart, G. R., Price, M. T., Wang, G., & Labruyere, J. (1990) · Experimental Neurology · doi:10.1016/0014-4886(90)90134-e · Cited by 128
Genetics of Parkinson's disease
Gasser, T. (2001) · Journal of Neurology · doi:10.1007/s004150170066 · Cited by 124
Diffusion of free nitric oxide
Lancaster, J. R. (1996) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(96)68007-0 · Cited by 119
Drukarch, B., Schepens, E., Stoof, J. C., Langeveld, C. H., & Muiswinkel, F. L. V. (1998) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(98)00050-1 · Cited by 119
Jenner, P. G. (2003) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(02)00115-3 · Cited by 119
Dopamine transporter mRNA expression is intense in rat midbrain neurons and modest outside midbrain
Cerruti, C., Walther, D. M., Kuhar, M. J., & Uhl, G. R. (1993) · Molecular Brain Research · doi:10.1016/0169-328x(93)90187-t · Cited by 119
Etiology of Parkinson's disease: Genetics and environment revisited
Steece‐Collier, K., Lad, E. M., & Kordower, J. H. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.242594999 · Cited by 115
Kuhn, D. M., Aretha, C. W., & Geddes, T. J. (1999) · Journal of Neuroscience · doi:10.1523/jneurosci.19-23-10289.1999 · Cited by 114
Genetics of Parkinson's disease.
Gasser, T. (2004) · Europe PMC (PubMed Central) · Cited by 111
Russ, H., Staudt, K., Martel, F., Gliese, M., & Schömig, E. (1996) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1996.tb01294.x · Cited by 109
Jan, C., François, C., Tandé, D., Yelnik, J., Tremblay, L., Agid, Y., & Hirsch, É. C. (2000) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2000.01351.x · Cited by 105
Kalaria, R. N., Mitchell, M. J., & Harik, S. I. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.10.3521 · Cited by 105
Kirschner, P. B., Jenkins, B. G., Schulz, J. B., Finkelstein, S. P., Matthews, R. T., Rosen, B. R., & Beal, M. F. (1996) · Brain Research · doi:10.1016/0006-8993(95)01513-2 · Cited by 99
Lan, J., & Jiang, D. (1997) · Journal of Neural Transmission · doi:10.1007/bf01291883 · Cited by 99
Coenzyme Q10 in Neurodegenerative Diseases
Shults, C. W. (2003) · Current Medicinal Chemistry · doi:10.2174/0929867033456882 · Cited by 99
Parametric mapping of [18F]FPCIT binding in early stage Parkinson's disease: A PET study
Ma, Y., DHAWAN, V. M., Mentis, M. J., Chaly, T., Spetsieris, P. G., & Eidelberg, D. (2002) · Synapse · doi:10.1002/syn.10090 · Cited by 98
Etiology of Parkinson's Disease
Huang, Z., de la Fuente‐Fernández, R., & Stoessl, A. J. (2003) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s031716710000319x · Cited by 95
Association of a polymorphism in the dopamine‐transporter gene with parkinson's disease
Couteur, D. G. L., Leighton, P. W., McCann, S. J., & Pond, S. M. (1997) · Movement Disorders · doi:10.1002/mds.870120523 · Cited by 95
Animal models of Parkinson’s disease in rodents induced by toxins: an update
Hirsch, É. C., Höglinger, G. U., Rousselet, E., Breidert, T., Parain, K., Féger, J., Ruberg, M., Prigent, A., Cohen‐Salmon, C., & Launay, J. (2003) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-0643-3_6 · Cited by 94
Inazu, M., Takeda, H., & Matsumiya, T. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01566.x · Cited by 91
Rollema, H., Kuhr, W. G., Kranenborg, G. L., et al. (1988) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)24064-2 · Cited by 87
Astrocytes as a primary locus for the conversion MPTP into MPP+
Brooks, W. J., Jarvis, M. F., & Wagner, G. C. (1989) · Journal of Neural Transmission · doi:10.1007/bf01244987 · Cited by 87
Sonsalla, P. K., & Heikkila, R. E. (1988) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(88)90054-1 · Cited by 86
Hadjiconstantinou, M., Fitkin, J. G., Dalia, A., & Neff, N. H. (1991) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1991.tb03776.x · Cited by 82
Hazell, A. S., Itzhak, Y., Liu, H., & Norenberg, M. D. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.68052216.x · Cited by 80
Glial Cell Reactions in Neurodegenerative Diseases Pathophysiology and Therapeutic Interventions
McGeer, P. L., & McGeer, E. G. (1998) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199803001-00001 · Cited by 79
Nakajima, K., Hida, H., Shimano, Y., Fujimoto, I., Hashitani, T., Kumazaki, M., Sakurai, T., & Nishino, H. (2001) · Brain Research · doi:10.1016/s0006-8993(01)02866-9 · Cited by 78
Hirrlinger, J., Schulz, J. B., & Dringen, R. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01013.x · Cited by 73
Glial HO-1 expression, iron deposition and oxidative stress in neurodegenerative diseases
Schipper, H. M. (1999) · Neurotoxicity Research · doi:10.1007/bf03033339 · Cited by 72
Selective MPP+ uptake into synaptic dopamine vesicles: possible involvement in MPTP neurotoxicity
Zompo, M. D., Piccardi, M. P., Ruiu, S., Quartu, M., GESSA, G. L., & Vaccari, A. (1993) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1993.tb13584.x · Cited by 69
Mizuno, Y., Sone, N., Suzuki, K., & Saitoh, T. (1988) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(88)90010-x · Cited by 66
Iron as catalyst for oxidative stress in the pathogenesis of Parkinson's disease?
Kienzl, E., Jellinger, K. A., Stachelberger, H., & Linert, W. (1999) · Life Sciences · doi:10.1016/s0024-3205(99)00458-0 · Cited by 62
Heaton, M. B., Paiva, M., Madorsky, I., Mayer, J., & Moore, D. B. (2003) · Developmental Brain Research · doi:10.1016/s0165-3806(02)00610-7 · Cited by 62
Astrocyte Mitochondria: A Substrate for Iron Deposition in the Aging Rat Substantia Nigra
Schipper, H. M., Vininsky, R., Brull, R., Small, L., & Brawer, J. R. (1998) · Experimental Neurology · doi:10.1006/exnr.1998.6854 · Cited by 60
COX-2 and Alzheimer’s disease: potential roles in inflammation and neurodegeneration
O’Banion, M. K. (1999) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.8.10.1521 · Cited by 59
Cerebral alterations in a MPTP-mouse model of Parkinson?s disease ? an immunocytochemical study
Muramatsu, Y., Kurosaki, R., Watanabe, H., Michimata, M., Matsubara, M., Imai, Y., & Araki, T. (2003) · Journal of Neural Transmission · doi:10.1007/s00702-003-0021-y · Cited by 58
Petersén, Å., Larsen, K. E., Behr, G. G., Romero, N., Przedborski, S., Brundin, P., & Sulzer, D. (2001) · Brain Research Bulletin · doi:10.1016/s0361-9230(01)00580-9 · Cited by 57
Date, I., Aoi, M., Tomita, S., Collins, F., & Ohmoto, T. (1998) · Neuroreport · doi:10.1097/00001756-199807130-00039 · Cited by 54
Iron, melanin and dopamine interaction: relevance to parkinson's disease
Ben‐Shachar, D., & Youdim, M. B. H. (1993) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(93)90038-t · Cited by 54
Riachi, N. J., & Harik, S. I. (1988) · Life Sciences · doi:10.1016/0024-3205(88)90189-0 · Cited by 54
Features of the Dopaminergic Neurotoxin MPTP
Kopin, I. J. (1992) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1992.tb24527.x · Cited by 53
Strain‐dependent susceptibility to MPTP and MPP‐induced Parkinsonism is determined by glia
Smeyne, M., Goloubeva, O. G., & Smeyne, R. J. (2001) · Glia · doi:10.1002/glia.1042.abs · Cited by 52
Self-citationCheng, F., Ni, D.-R., Wu, M., Kuo, J., & Chia, L. (1998) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00554-0 · Cited by 50
Etiology of Parkinson's Disease
Stoessl, A. J. (1999) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100000032 · Cited by 50
Multiple Astrocyte Transcripts Encode Nigral Trophic Factors in Rat and Human
Schaar, D. G., Sieber, B.-A., Sherwood, A. C., Dean, D., Mendoza, G., Ramakrishnan, L., Dreyfus, C. F., & Black, I. B. (1994) · Experimental Neurology · doi:10.1006/exnr.1994.1218 · Cited by 48
Genetic Epidemiology of Parkinson's Disease
Payami, H., & Zareparsi, S. (1998) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/089198879801100207 · Cited by 48
Brecknell, J. E., Dunnett, S. B., & Fawcett, J. W. (1995) · Neuroscience · doi:10.1016/0306-4522(94)00370-k · Cited by 46
Polymorphisms of dopamine receptor and transporter genes and Parkinson's disease
Higuchi, S., Muramatsu, T., Arai, H., Hayashida, M., Sasaki, H., & Trojanowski, J. Q. (1995) · Journal of Neural Transmission - Parkinsons Disease and Dementia Section · doi:10.1007/bf02251226 · Cited by 46
Astrocytes as the site for bioactivation of neurotoxins.
Monte, D. A. D., Royland, J. E., Irwin, I., & Jw, L. (1996) · PubMed · Cited by 46
Levodopa – an exotoxin or a therapeutic drug?
Melamed, E., Offen, D., Shirvan, A., & Ziv, I. (2000) · Journal of Neurology · doi:10.1007/pl00022914 · Cited by 44
Do dopamine agonists or levodopa modify Parkinson's disease progression?
MAREK, K. L., Jennings, D. L., & Seibyl, J. P. (2002) · European Journal of Neurology · doi:10.1046/j.1468-1331.9.s3.2.x · Cited by 43
MPTP selectively induces haem oxygenase‐1 expression in striatal astrocytes
Fernandez‐Gonzalez, A., Pérez‐Otaño, I., & Morgan, J. I. (2000) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2000.00044.x · Cited by 43
Fornai, F., Battaglia, G., Gesi, M., et al. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02999-1 · Cited by 42
Gong, L., Wyatt, R. J., Baker, I., & Masserano, J. M. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00148-2 · Cited by 41
Youdim, M. B. H., Grünblatt, E., Levites, Y., Maor, G., & Mandel, S. A. (2002) · Neurotoxicity Research · doi:10.1080/1029842021000045507 · Cited by 40
McNaught, K. S. P., Thull, U., Carrupt, P., et al. (1996) · Biochemical Pharmacology · doi:10.1016/0006-2952(96)00091-3 · Cited by 38
Suzuki, K., Mizuno, Y., & Yoshida, M. (1990) · PubMed · Cited by 38
Regulation of heme oxygenase-1 expression by dopamine in cultured C6 glioma and primary astrocytes
Schmidt, J. E., Mertz, K. D., & Morgan, J. I. (1999) · Molecular Brain Research · doi:10.1016/s0169-328x(99)00231-4 · Cited by 37
FGF‐2 in the MPTP model of parkinson's disease: Effects on astroglial cells
Otto, D., & Unsicker, K. (1994) · Glia · doi:10.1002/glia.440110107 · Cited by 35
Recent Advances in Research on Parkinson Disease: Synuclein and Parkin
Burke, R. E. (2004) · The Neurologist · doi:10.1097/01.nrl.0000117822.90759.83 · Cited by 34
The Case of the Frozen Addicts
Palfreman, J., & Langston, J. W. (1995) · Cited by 33
The Clinical Syndrome of Striatal Dopamine Deficiency: Parkinsonism Induced by MPTP
Eldridge, R., & Rocca, W. A. (1985) · New England Journal of Medicine · doi:10.1056/nejm198510313131813 · Cited by 29
The α-synuclein gene is not a major risk factor in familial Parkinson disease
Scott, W. K., Yamaoka, L. H., Stajich, J. M., Scott, B. L., Vance, J. M., Roses, A. D., Pericak‐Vance, M. A., Watts, R. L., NANCE, M. A., Hubble, J. P., et al. (1999) · Neurogenetics · doi:10.1007/s100480050083 · Cited by 29
Production and disposition of 1‐methyl‐4‐phenylpyridinium in primary cultures of mouse astrocytes
Monte, D. A. D., Wu, E. Y., Irwin, I., DeLanney, L. E., & Langston, J. W. (1992) · Glia · doi:10.1002/glia.440050108 · Cited by 28
Cook, R., Lu, L., Gu, J., Williams, R. W., & Smeyne, R. J. (2003) · Molecular Brain Research · doi:10.1016/s0169-328x(02)00659-9 · Cited by 28
Self-citationAccumulation of 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine in Cultured Cerebellar Astrocytes
Marini, A. M., Lipsky, R. H., Schwartz, J. P., & Kopin, I. J. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb11336.x · Cited by 21
Hu, C., Sung, S., Liu, H., & Chang, J. (1999) · European Neurology · doi:10.1159/000008008 · Cited by 20
Lau, Y., Fung, Y. K., Trobough, K. L., Cashman, J., & Wilson, J. A. (1991) · PubMed · Cited by 15
Research works printed but not linked: 11
- Hansen, 1994, Bilirubin in the brain. distribution and effects on neurophysiological and neurochemical processes, Clin. Pediatr. (Phila), 33, 452, 10.1177/000992289403300802 · doi:10.1177/000992289403300802
- Hatakeyama, 1996, Mechanism for mouse strain differences in the protective effect of sudan III against the in vivo genotoxicity of 7, 12-dimethylbenz[a]anthracene, Toxicol. Lett., 89, 231, 10.1016/S0378-4274(96)03825-8 · doi:10.1016/s0378-4274(96)03825-8
- Kitayama, 1993, Dopamine transporter mutants selectively enhance MPP+ transport, Synapse, 15, 58, 10.1002/syn.890150107 · doi:10.1002/syn.890150107
- Langston, 1985, The case of the tainted heroin, Sciences, 25, 34, 10.1002/j.2326-1951.1985.tb02766.x · doi:10.1002/j.2326-1951.1985.tb02766.x
- Levine, 1983, Effects of neonatal destruction of the medial forebrain bundle in the cat: long-term neurochemical, locomotor, and regulatory deficits, Exp. Neurol., 81, 340, 10.1016/0014-4886(83)90268-6 · doi:10.1016/0014-4886(83)90268-6
- Mitra, 1994, Resistance of golden hamster to 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine: relationship with low levels of regional monoamine oxidase B, J. Neurochem., 62, 1906, 10.1046/j.1471-4159.1994.62051906.x · doi:10.1046/j.1471-4159.1994.62051906.x
- Mizuno, 1988, Studies on the toxicity of 1-methyl-4-phenylpyridinium ion (MPP+) against mitochondria of mouse brain, J. Neurol. Sci., 86, 97, 10.1016/0022-510X(88)90010-X · DOI
- Ofori, 1987, Effects of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) on dopamine synthesis and release in the rabbit retina in vitro, Neuropharmacology, 26, 1607, 10.1016/0028-3908(87)90009-8 · doi:10.1016/0028-3908(87)90009-8
- Riachi, 1988, On the mechanisms underlying 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity: II. Susceptibility among mammalian species correlates with the toxin's metabolic patterns in brain microvessels and liver, JPET, 244, 443
- Riachi, 1990, Effects of internal carotid administration of MPTP on rat brain and blood–brain barrier, Brain Res., 533, 6, 10.1016/0006-8993(90)91788-I · doi:10.1016/0006-8993(90)91788-i
- Schmidt, 1984, In vitro release of tritiated monoamines from rat CNS tissue by the neurotoxic compound 1-methyl-phenyl-tetrahydropyridine, Eur. J. Pharmacol., 103, 255, 10.1016/0014-2999(84)90485-0 · doi:10.1016/0014-2999(84)90485-0
Cited by
Bender, A., Krishnan, K. J., Morris, C. M., Taylor, G. A., Reeve, A. K., Perry, R. H., Jaros, E., Hersheson, J. S., Betts, J., Klopstock, T., et al. (2006) · Nature Genetics · doi:10.1038/ng1769 · Cited by 1,570
Gillies, G. E., & McArthur, S. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002071 · Cited by 733
Thioredoxin and Related Molecules–From Biology to Health and Disease
Lillig, C. H., & Holmgren, A. (2007) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.9.25 · Cited by 724
Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons
Ekstrand, M. I., Terzioglu, M., Galter, D., Zhu, S., Hofstetter, C., Lindqvist, E., Thams, S., Bergstrand, A., Hansson, F. S., Trifunovic, A., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605208103 · Cited by 605
Neurotoxicity of pesticides: a brief review
Costa, L. (2008) · Frontiers in Bioscience · doi:10.2741/2758 · Cited by 449
Metadata
- Authors
- Smeyne, R. J., & Jackson-Lewis, V.
- Venue
- Molecular Brain Research
- Publisher
- Elsevier BV
- Published
- 2005-03
- Volume
- 134
- Issue
- 1
- Pages
- 57-66
- ISSN
- 0169-328X (ISSN-L)
- OpenAlex
- W2031315586
- Cited by
- 377
- References
- 154
- FWCI
- 7.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.